Wall Street expects Mineralys Therapeutics to report zero revenue and a consensus EPS loss of $0.55 for the third quarter, with the stock currently trading at $16.89 compared to a $45.50 average analyst price target.
The primary focus for investors is clinical and regulatory progress for lorundrostat, specifically updates on the Phase 3 Launch-HTN trial and the anticipated timeline for a New Drug Application (NDA) submission.
Recent data presentations at ASN Kidney Week 2026 demonstrated the drug candidate's efficacy in hypertension patients with chronic kidney disease, reinforcing its potential market differentiation. However, concerns remain regarding the company's cash burn and its ability to fund operations through commercialization after a significant earnings miss in the previous quarter.